Revolutionary at-home blood test device launched to support cancer patients
The new device will patients to monitor key health indicators from their own homes
Last updated 17th Sep 2025
A new at-home blood testing device, Liberty, is set to transform cancer care by allowing patients to monitor key health indicators from their own homes. Developed by Entia, the device was inspired by CEO Toby Basey-Fisher’s firsthand experience of the challenges faced by people undergoing cancer treatment.
“Liberty was created after seeing just how difficult and complex the cancer treatment journey can be for patients and their families,” Basey-Fisher explained. “During therapy, patients often have to attend routine blood tests multiple times over months, which is time-consuming and stressful. Our aim is to give people more control and more time at home.”
The device allows patients to take simple finger-prick blood tests, with results instantly uploaded to the cloud and accessible to healthcare professionals. “This means decisions about treatment can be made in under an hour, rather than patients waiting half a day in a hospital,” Basey-Fisher said.
The innovation is expected to benefit both patients and hospitals. Patients gain more time at home and greater control over their care, while healthcare teams can focus on more urgent cases, freeing up clinic capacity. “Instead of routine tests taking up clinic time, nurses and phlebotomists can focus on patients who need them most,” Basey-Fisher added.
The system also allows closer monitoring of white blood cell counts, helping to identify infection risks and prevent complications such as sepsis. “By tracking how patients’ bodies respond to treatment, we can intervene early and even prevent hospitalisations,” he said.
Liberty has already been piloted in Shrewsbury and Telford, with patients reporting they regained valuable days of life with loved ones during treatment. “Some patients on palliative care have told us they’ve been able to spend eight to ten extra days at home with family because of this device,” Basey-Fisher said.
Basey-Fisher also highlighted the potential for the technology to evolve. “We see Liberty as the tip of the iceberg. Just as continuous glucose monitors revolutionised diabetes care, this device could create real-time insights in cancer treatment, helping both patients and clinicians make better, faster decisions.”
“This innovation gives patients back time at home when it matters most, while supporting clinicians to make faster, informed decisions,” he said. “It’s incredibly rewarding to see the impact on patients’ lives.”
Shropshire hospitals are among the first in the country to offer Liberty, marking a major step forward in rural cancer care.